AbbVie (Allergan Aesthetics' parent) filed three material events with the SEC in recent months (April 29, May 12, and June 22, 2026), indicating significant business developments affecting the aesthetics division. While the specific details are not yet public, material events of this frequency and timing typically signal pricing adjustments, rebate restructuring, or changes to loyalty program terms — the mechanisms that directly impact injector margins.